Extended Data Fig. 5: Interferon alpha and gamma signature and association with PFS.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
(a) Kaplan-Meier curve estimating PFS according to up or stable/downregulation of interferon alfa (p-value = 0.258) (n = 22); (b) Kaplan-Meier curve estimating PFS according to up or stable/downregulation of interferon gamma (p-value = 0.045).
